Trastuzumab Emtansine Mixture from Japan
Immunological preparation mixing trastuzumab monoclonal antibody with emtansine for HER2-positive breast cancer treatment. Falls under HTS 3002.14.0010 due to monoclonal antibody content in a mixed, non-retail bulk form for hospital use. Includes buffers and stabilizers as mixed components.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Provide BLA (Biologics License Application) details and confirm monoclonal antibody specificity in import docs
• Maintain 2-8°C cold chain; include temperature monitoring logs to prevent denaturation during transit
• Declare as mixed product; single-component antibody-drug conjugates may require different classification review